Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of MCLA-128-based Combinations in Metastatic Breast Cancer (MBC): MCLA-128/Trastuzumab/Chemotherapy in HER2-positive MBC and MCLA-128/Endocrine Therapy in Estrogen Receptor Positive and Low HER2 Expression MBC

NCT03321981 is registered in ClinicalTrials.gov with Merus B.V. as lead sponsor.

NCT NCT03321981
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03321981 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of MCLA-128-based Combinations in Metastatic Breast Cancer (MBC): MCLA-128/Trastuzumab/Chemotherapy in HER2-positive MBC and MCLA-128/Endocrine Therapy in Estrogen Receptor Positive and Low HER2 Expression MBC
Lead sponsor
Merus B.V.
Phase
Phase 2
Overall status
Completed
Start date
January 15, 2018
Completion date
July 26, 2023
Enrollment
105 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer metastatic